Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:Cholesterol acyltransferase produced by gene-transduced adipocytes in vitro

Molecular Genetics and Metabolism

Volumn 102, Issue 2, 2011, Pages 229-231

  Asada, Sakiyo ^a,b   Kuroda, Masayuki ^a,b   Aoyagi, Yasuyuki ^a,b   Bujo, Hideaki ^a   Tanaka, Shigeaki ^b   Konno, Shunichi ^b   Tanio, Masami ^a   Ishii, Itsuko ^b   Aso, Masayuki ^b   Saito, Yasushi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CellGenTech Inc   (Japan)

Author keywords

Apolipoprotein A I; Familial LCAT deficiency; Fish eye disease; Lecithin:cholesterol acyltransferase; Protein replacement therapy

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ADIPOCYTE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME REPLACEMENT; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNODETECTION; IN VITRO STUDY; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; PRIORITY JOURNAL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADIPOCYTES; APOLIPOPROTEIN A-I; CELLS, CULTURED; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LECITHIN ACYLTRANSFERASE DEFICIENCY; MALE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 78651463927     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.10.009     Document Type: Article

References (20)

1. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 2005, 96:1221-1232.
2. Santamarina-Fojo S., Hoeg J.M., Assman G., Brewer H.B. Lecithin cholesterol acyltransferase deficiency and fish eye disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 2817-2833. McGraw-Hill Inc., New York. 8th Eds. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler, B.F. Volkman (Eds.).
3. M. Kuroda, Y. Aoyagi, S. Asada, H. Bujo, S. Tanaka, S. Konno, M. Tanio, I Ishii, K. Machida, F. Matsumoto, K. Satoh, M. Aso, Y. Saito, Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency. Gene Ther Mol Biol; in press.
4. Funke H., von Eckardstein A., Pritchard P.H., Albers J.J., Kastelein J.J., Droste C., Assmann G. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc. Natl Acad. Sci. USA 1991, 88:4855-4859.
5. Holmquist L., Carlson L.A. Normalization of high density lipoprotein in fish eye disease plasma by purified normal human lecithin: cholesterol acyltransferase. Lipids 1988, 23:225-229.
6. von Eckardstein A., Huang Y., Wu S., Funke H., Noseda G., Assmann G. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Arterioscler. Thromb. Vasc. Biol. 1995, 15:691-703.
7. Asztalos B.F., Schaefer E.J., Horvath K.V., Yamashita S., Miller M., Franceschini G., Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J. Lipid Res. 2007, 48:592-599.
8. Nakamura Y., Kotite L., Gan Y., Spencer T.A., Fielding C.J., Fielding P.E. Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase. Biochemistry 2004, 43:14811-14820.
9. Albers J.J., Chen C.H., Adolphson J.L. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J. Lipid Res. 1981, 22:1206-1213.
10. Miida T., Miyazaki O., Hanyu O., Nakamura Y., Hirayama S., Narita I., Gejyo F., Ei I., Tasaki K., Kohda Y., Ohta T., Yata S., Fukamachi I., Okada M. LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J. Am. Soc. Nephrol. 2003, 14:732-738.
11. Ronti T., Lupattelli G., Mannarino E. The endocrine function of adipose tissue: an update. Clin. Endocrinol. 2006, 64:355-365.
12. Ito M., Bujo H., Takahashi K., Arai T., Tanaka I., Saito Y. Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice. Diabetologia 2005, 48:1614-1620.
13. Shibasaki M., Bujo H., Takahashi K., Murakami K., Unoki H., Saito Y. Catalytically inactive lipoprotein lipase overexpression increases insulin sensitivity in mice. Horm. Metab. Res. 2006, 38:491-496.
14. Kitagawa Y., Bujo H., Takahashi K., Shibasaki M., Ishikawa K., Yagui K., Hashimoto N., Noda K., Nakamura T., Yano S., Saito Y. Impaired glucose tolerance is accompanied by decreased insulin sensitivity in tissues of mice implanted with cells that overexpress resistin. Diabetologia 2004, 47:1847-1853.
15. Kubota Y., Unoki H., Bujo H., Rikihisa N., Udagawa A., Yoshimoto S., Ichinose M., Saito Y. Low-dose GH supplementation reduces the TLR2 and TNF-alpha expressions in visceral fat. Biochem. Biophys. Res. Commun. 2008, 368:81-87.
16. Sorci-Thomas M.G., Bhat S., Thomas M.J. Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices. Clin. Lipidol. 2009, 4:113-124.
17. Jonas A. Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta 2000, 1529:245-256.
18. Manabe M., Abe T., Nozawa M., Maki A., Hirata M., Itakura H. H, New substrate for determination of serum lecithin:cholesterol acyltransferase. J. Lipid Res. 1987, 28:1206-1215.
19. Taira K., Bujo H., Kobayashi J., Takahashi K., Miyazaki A., Saito Y. Positive family history for coronary heart disease and 'midband lipoproteins' are potential risk factors of carotid atherosclerosis in familial hypercholesterolemia. Atherosclerosis 2002, 160:391-397.
20. Harris W.S., Rayford A. LCAT inhibitors interfere with the enzymatic determination of cholesterol and triglycerides. Lipids 1990, 25:341-343.